{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T21:04:32.648875+00:00","company":{"ticker":"EVH","cik":1628908,"company_name":"Evolent Health, Inc."},"pagination":{"limit":100,"returned":11,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"ed3dea8bd8521276f7acf097551cafdf2fa74f8d","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2026-06-04T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"15,840,304","subject":null,"votes_abstain":"126,885","votes_against":"18,712,636","votes_for":"47,536,873","votes_withheld":null}]},"claim":"Evolent Health, Inc. shareholders approved Amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan at the 2026-06-04 meeting.","evidence_excerpt":"The Company’s stockholders approved the amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, as set forth below:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-26-000037","anchor_url":"https://secwatch.observer/filing/0001628908-26-000037#claim-ed3dea8bd8521276f7acf097551cafdf2fa74f8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890826000037/0001628908-26-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cb3fd15e9ae43cbafeafcb1c80757244bd4087da","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2026-06-04T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Advisory approval of compensation of named executive officers for 2025","proposal_type":"say_on_pay","results":[{"broker_non_votes":"15,840,304","subject":null,"votes_abstain":"84,119","votes_against":"7,922,802","votes_for":"58,369,473","votes_withheld":null}]},"claim":"Evolent Health, Inc. shareholders approved Advisory approval of compensation of named executive officers for 2025 at the 2026-06-04 meeting.","evidence_excerpt":"The Company’s stockholders approved the compensation of our named executive officers for 2025 on an advisory basis, as set forth below:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-26-000037","anchor_url":"https://secwatch.observer/filing/0001628908-26-000037#claim-cb3fd15e9ae43cbafeafcb1c80757244bd4087da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890826000037/0001628908-26-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"96c1f2c9d4822aec3201b68ee8335480743e1554","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2026-06-04T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"55,493","votes_against":"124,362","votes_for":"82,036,843","votes_withheld":null}]},"claim":"Evolent Health, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 as set forth below:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-26-000037","anchor_url":"https://secwatch.observer/filing/0001628908-26-000037#claim-96c1f2c9d4822aec3201b68ee8335480743e1554","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890826000037/0001628908-26-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c6ce3e851b04f98a1e37d64868c854e5ccde9929","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2026-06-04T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Election of ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the 2027 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"15,840,303","subject":"Toyin Ajayi, MD","votes_abstain":"90,502","votes_against":null,"votes_for":"60,373,601","votes_withheld":"5,912,292"},{"broker_non_votes":"15,840,305","subject":"Craig Barbarosh","votes_abstain":"90,471","votes_against":null,"votes_for":"65,818,775","votes_withheld":"467,147"},{"broker_non_votes":"15,840,302","subject":"Seth Blackley","votes_abstain":"58,810","votes_against":null,"votes_for":"60,323,961","votes_withheld":"5,993,625"},{"broker_non_votes":"15,840,302","subject":"Russell Glass","votes_abstain":"77,670","votes_against":null,"votes_for":"60,316,659","votes_withheld":"5,982,067"},{"broker_non_votes":"15,840,302","subject":"Peter Grua","votes_abstain":"90,496","votes_against":null,"votes_for":"60,324,441","votes_withheld":"5,961,459"},{"broker_non_votes":"15,840,303","subject":"Shawn Guertin","votes_abstain":"97,653","votes_against":null,"votes_for":"65,881,893","votes_withheld":"396,849"},{"broker_non_votes":"15,840,303","subject":"Richard Jelinek","votes_abstain":"78,965","votes_against":null,"votes_for":"60,027,846","votes_withheld":"6,269,584"},{"broker_non_votes":"15,840,304","subject":"Kim Keck","votes_abstain":"65,860","votes_against":null,"votes_for":"60,178,555","votes_withheld":"6,131,979"},{"broker_non_votes":"15,840,303","subject":"Jill Smith","votes_abstain":"54,773","votes_against":null,"votes_for":"65,919,489","votes_withheld":"402,133"},{"broker_non_votes":"15,840,304","subject":"Brendan Springstubb","votes_abstain":"97,900","votes_against":null,"votes_for":"65,810,202","votes_withheld":"468,292"}]},"claim":"Evolent Health, Inc. shareholders approved Election of ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the 2027 annual meeting at the 2026-06-04 meeting.","evidence_excerpt":"The Company’s stockholders elected ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below:","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-26-000037","anchor_url":"https://secwatch.observer/filing/0001628908-26-000037#claim-c6ce3e851b04f98a1e37d64868c854e5ccde9929","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890826000037/0001628908-26-000037-index.htm"},{"fact_type":"earnings_release","fact_key":"85e75739dc7aaa5dd74f36047ee7a6b8b8f17d36","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(26,632)","period_text":"quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$496,246"},"claim":"Evolent Health, Inc. reported quarter ended March 31, 2026 results: revenue $496,246, net income $(26,632).","evidence_excerpt":"March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case): For the Three Months Ended March 31, 2026 2025 Financial Results: Revenue $ 496,246 $ 483,649 Net loss attributable to common shareholders of Evolent Health, Inc. $ (26,632) $ (72,250) Net loss margin (5.4) % (14.9) % Adjusted EBITDA $ 22,067 $ 36,860 Adjusted","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-26-000031","anchor_url":"https://secwatch.observer/filing/0001628908-26-000031#claim-85e75739dc7aaa5dd74f36047ee7a6b8b8f17d36","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/0001628908-26-000031-index.htm"},{"fact_type":"executive_change","fact_key":"4200ea555e","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2025-04-22T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Diane Holder departed as Director at Evolent Health, Inc..","evidence_excerpt":"Diane Holder notified the Board of Directors (the “Board”) of Evolent Health, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 5, 2025 (the “2025 Annual Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628908-25-000055","anchor_url":"https://secwatch.observer/filing/0001628908-25-000055#claim-4200ea555e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890825000055/0001628908-25-000055-index.htm"},{"fact_type":"executive_change","fact_key":"d162a2fafe","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2025-02-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Brendan Springstubb was appointed as Director at Evolent Health, Inc..","evidence_excerpt":"On February 4, 2025, the Board (1) appointed Mr. Springstubb as a director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628908-25-000010","anchor_url":"https://secwatch.observer/filing/0001628908-25-000010#claim-d162a2fafe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890825000010/0001628908-25-000010-index.htm"},{"fact_type":"executive_change","fact_key":"844ea963cf","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2025-02-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"M. Bridget Duffy resigned as Director at Evolent Health, Inc..","evidence_excerpt":"On February 3, 2025, M. Bridget Duffy, MD resigned from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628908-25-000010","anchor_url":"https://secwatch.observer/filing/0001628908-25-000010#claim-844ea963cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890825000010/0001628908-25-000010-index.htm"},{"fact_type":"earnings_release","fact_key":"61b35622a375ac78dea7bd94312601f6768aa423","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$(25.2) million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$639.7 million"},"claim":"Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.","evidence_excerpt":"Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-24-000051","anchor_url":"https://secwatch.observer/filing/0001628908-24-000051#claim-61b35622a375ac78dea7bd94312601f6768aa423","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/0001628908-24-000051-index.htm"},{"fact_type":"earnings_release","fact_key":"10e4c693423423727fe3d60dded6f54a7e925a04","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2024","report_date":"2024-02-22","result_type":"guidance_update","revenue_text":null},"claim":"Evolent Health, Inc. updated its 2024 guidance (initiated).","evidence_excerpt":"Provides initial outlook for 2024 in line with long-term targets","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628908-24-000015","anchor_url":"https://secwatch.observer/filing/0001628908-24-000015#claim-10e4c693423423727fe3d60dded6f54a7e925a04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm"},{"fact_type":"earnings_release","fact_key":"f523e17ef72150af41719485e8fdd4fcf1c67162","cik":1628908,"ticker":"EVH","company_name":"Evolent Health, Inc.","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"($41,395) thousand, ($142,260) thousand","period_text":"the quarter and year ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$556,055 thousand, $1,963,896 thousand"},"claim":"Evolent Health, Inc. reported the quarter and year ended December 31, 2023 results: revenue $556,055 thousand, $1,963,896 thousand, net income ($41,395) thousand, ($142,260) thousand.","evidence_excerpt":"Evolent Announces Fourth Quarter and Full Year 2023 Results • Full year revenue of $1,963.9 million, 45% growth over 2022 • Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628908-24-000015","anchor_url":"https://secwatch.observer/filing/0001628908-24-000015#claim-f523e17ef72150af41719485e8fdd4fcf1c67162","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm"}]}